重症患者持续输注4%白蛋白的初步研究:通过减少氧化底物降低医院感染
该前瞻性随机开放标签初步研究纳入50例血清白蛋白低于20 g/L的休克患者,在持续使用去甲肾上腺素期间分别接受持续4%白蛋白输注或间断20%白蛋白输注。18天内,持续4%白蛋白组定植事件为4次对12次(p=0.035),医院感染为2次对13次(p=0.002),均低于对照组。体外研究显示白蛋白与vasostatin-I的二硫键环(残基17-40)相互作用,持续4%白蛋白输注恢复其抗菌活性所需的氧化状态。作者认为持续4%白蛋白通过增加抗菌性vasostatin-I的可用性有效减少休克患者的护理相关感染,可能指导未来休克患者的管理。
要点
- 研究纳入50例血清白蛋白低于20 g/L的休克患者,在持续去甲肾上腺素输注期间随机接受持续4%白蛋白或间断20%白蛋白。
- 18天内持续4%白蛋白组定植事件4次,间断20%白蛋白组12次(p=0.035)。
- 18天内持续4%白蛋白组医院感染2次,间断20%白蛋白组13次(p=0.002)。
- 体外实验显示白蛋白与vasostatin-I残基17-40的二硫键环相互作用,持续4%白蛋白输注恢复其抗菌活性所需的氧化状态。
- 作者结论认为持续4%白蛋白通过增加抗菌性vasostatin-I的可用性有效减少护理相关感染,可能指导未来休克患者管理。
适用人群与场景
- 休克患者,血清白蛋白低于20 g/L,在持续输注去甲肾上腺素期间接受白蛋白治疗。
- 研究在每年收治1000例患者的三级ICU进行。
诊断标准与关键阈值
- 血清白蛋白低于20 g/L。
- 休克状态且正在持续输注去甲肾上腺素。
处置流程与药物剂量
- 持续4%白蛋白输注组:在持续输注去甲肾上腺素期间持续给予4%白蛋白。
- 间断20%白蛋白输注组:在持续输注去甲肾上腺素期间间断给予20%白蛋白。
研究设计与关键结果
- 前瞻性随机开放标签初步研究,纳入50例血清白蛋白低于20 g/L的休克患者,比较持续4%白蛋白与间断20%白蛋白输注。
- 18天内定植事件:持续4%白蛋白组4次 vs 间断20%白蛋白组12次(p=0.035)。
- 18天内医院感染:持续4%白蛋白组2次 vs 间断20%白蛋白组13次(p=0.002)。
- 体外研究显示白蛋白与vasostatin-I的二硫键环(残基17-40)相互作用,持续4%白蛋白输注恢复其抗菌活性所需的氧化状态。
证据类型、等级与局限
- 证据类型:前瞻性随机开放标签初步研究,含体内和体外转化研究分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为持续4%白蛋白通过增加抗菌性vasostatin-I的可用性有效减少休克患者的护理相关感染,可能指导未来休克患者的管理。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: Care-related infections affect up to 11% of ICU patients. Running therapeutic albumin is sometimes associated to less infection: whether a specific method of its infusion is of any interest to modulate innate defense is unknown. Our objectives were: 1) to test whether the method for albumin infusion is important to prevent care-related infections and 2) to analyze in vitro the antioxidative role of albumin on host defense proteins during shock (using vasostatin-I as an example).
DESIGN: In a prospective, randomized, open-label trial, shock patients were allocated to receive either continuously 4% albumin or intermittently 20% albumin, as long as they were infused with norepinephrine. A translational study including in vivo and in vitro analyses of albumin-vasostatin-I interactions is reported.
SETTING: A tertiary ICU caring for 1,000 patients per year.
PATIENTS: Fifty shock patients with serum albumin less than 20 g/L.
INTERVENTIONS: In vivo colonization and nosocomial infections were recorded and time-dependent changes in serum albumin, chromogranin A, and vasostatin-I concentrations as well. In vitro, we studied biochemical albumin-vasostatin-I relationship using biochemical methods.
MEASUREMENTS AND MAIN RESULTS: Over 18 days, we recorded a decrease in colonization (four vs 12 episodes; p = 0.035) and nosocomial infection frequency (two vs 13 episodes; p = 0.002) in patients infused continuously 4% albumin versus controls. In vitro, albumin interacts with the disulfide loop vasostatin-I (residues 17-40) and continuous 4% albumin infusion restores its oxidative status required for antimicrobial activity.
CONCLUSIONS: Continuous 4% albumin is effective in reducing care-related infections in shock patients by increasing the availability of antimicrobial vasostatin-I. This might guide future care of shock patients.
参考来源
- Schneider F, Dureau AF, Hellé S, et al. A Pilot Study on Continuous Infusion of 4% Albumin in Critically Ill Patients: Impact on Nosocomial Infection via a Reduction Mechanism for Oxidized Substrates. Crit Care Explor. 2019. PMID: 32166286. doi:10.1097/CCE.0000000000000044
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。